Merck & Co. (NYSE: MRK) announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748, an investigational bispecific antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE